Premium
Granisetron prevents nausea and vomiting during spinal anaesthesia for caesarean section
Author(s) -
Fujii Y.,
Tanaka H.,
Toyooka H.
Publication year - 1998
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1998.tb04922.x
Subject(s) - medicine , granisetron , nausea , anesthesia , vomiting , caesarean section , placebo , surgery , antiemetic , pregnancy , alternative medicine , pathology , biology , genetics
Background: Nausea and vomiting during spinal anaesthesia for caesarean section are common and unpleasant complications. This study was undertaken to evaluate the efficacy of granisetron, a selective 5‐hydroxytryptamine type 3 receptor antagonist, for prophylactic treatment of nausea and vomiting in parturients undergoing nonemergent caesarean section under spinal anaesthesia. Methods: In a randomized, double‐blind, placebo‐controlled trial, 100 patients, 21–38 years, received either placebo (saline) or granisetron at 3 different doses (20 μg · kg ‐1 , 40 μg · kg ‐1 or 80 μg · kg ‐1 ) (n=25 for each) intravenously immediately after clamping of the foetal umbilical cord. Nausea, vomiting and safety assessments were performed during spinal anaesthesia for caesarean section. Results: The treatment groups were similar with regard to maternal characteristics and operative management. The incidence of nausea and vomiting was 64%, 52%, 14% and 12% after administration of placebo and granisetron in a dose of 20 μg · kg ‐1 , 40 μg · kg ‐1 and 80 μg · kg ‐1 , respectively ( P <0.05; overall Fisher's exact probability test). No clinically important adverse effects were observed in any group. Conclusions: Prophylactic use of granisetron in a minimum dose of 40 μg · kg ‐1 is effective for preventing nausea and vomiting during spinal anaesthesia for caesarean section. © Acta Anaesthesiologiat Scandinavica 42 (1998)